Ganciclovir Dosing
For adults with normal renal function, use intravenous ganciclovir 5 mg/kg every 12 hours for induction therapy (14-21 days) followed by 5 mg/kg daily for maintenance; for children with CMV disease, use 5 mg/kg every 12 hours for induction, and for neonates with congenital CMV, use 6 mg/kg every 12 hours for 6 weeks. 1, 2
Adult Dosing
Standard Dosing (Normal Renal Function)
Induction therapy:
- 5 mg/kg IV every 12 hours for 14-21 days (for disseminated CMV disease including retinitis) 1, 2
- Infuse over 1-2 hours 1
Maintenance therapy:
- 5 mg/kg IV daily (or 6 mg/kg daily for 5 days/week) 2
- Oral: 1000 mg three times daily with food 3, 4
- Alternative: 500 mg six times daily every 3 hours with food during waking hours 4
Prophylaxis:
- Oral: 1000 mg three times daily with food 4
Renal Impairment Adjustments
Critical consideration: Ganciclovir is primarily renally excreted, making dose adjustment essential in renal dysfunction 4, 5. The terminal elimination half-life increases dramatically from 3.6 hours in normal renal function to 11.5 hours in renal insufficiency 5.
IV ganciclovir dose adjustments (for maintenance 5 mg/kg daily dosing) 3:
| Creatinine Clearance (mL/min) | Adjusted Dose |
|---|---|
| 50-69 | 2.5 mg/kg every 24 hours |
| 25-49 | 1.25 mg/kg every 24 hours |
| 10-24 | 0.625 mg/kg every 24 hours |
| <10 | 0.625 mg/kg three times weekly |
| Hemodialysis | 0.625 mg/kg after each dialysis |
Oral ganciclovir dose adjustments 3:
| Creatinine Clearance (mL/min) | Adjusted Dose |
|---|---|
| 50-69 | 1500 mg daily |
| 25-49 | 1000 mg daily |
| 10-24 | 500 mg daily |
| <10 | 500 mg three times weekly |
| Hemodialysis | 500 mg after each dialysis |
Important caveat: Hemodialysis removes approximately 53% of ganciclovir, so dosing should occur after dialysis 5. For sustained low-efficiency dialysis (SLED), use 2.5 mg/kg/day for 8-hour sessions and consider 5 mg/kg/day for 24-hour sessions 6.
Pediatric Dosing
Neonates with Congenital CMV
6 mg/kg IV every 12 hours for 6 weeks 1, 2
- This higher dose (12 mg/kg/day total) produces substantial viral load reduction 1
- Expect neutropenia in approximately two-thirds of infants; dose modification required in 48% 1
Children with HIV and CMV Disease
Induction therapy:
- 5 mg/kg IV every 12 hours for 14-21 days 1, 2
- May increase to 7.5 mg/kg IV twice daily if needed 2
- Infuse over 1-2 hours 1
Maintenance therapy:
- 5 mg/kg daily for 5-7 days per week 2
Oral ganciclovir (when appropriate):
- 30 mg/kg every 8 hours 1
- Children require higher oral doses than adults due to lower bioavailability and greater clearance 1
Pediatric Renal Impairment
Apply similar proportional dose reductions as adults based on creatinine clearance 7. For children with GFR <50 mL/min/1.73m², reduce starting dose by 50%; for GFR <25 mL/min/1.73m², reduce by 75% 7.
Critical Safety Considerations
Myelosuppression (Most Important Toxicity)
- Granulocytopenia, anemia, and thrombocytopenia occur frequently 1
- Dose reduction or interruption necessary in up to 40% of patients 1
- Do not administer if absolute neutrophil count <500/µL or platelets <25,000/µL 4
- Monitor complete blood counts and platelets frequently 2, 4
- Consider granulocyte colony-stimulating factor for severe neutropenia 1
Nephrotoxicity
- Monitor serum creatinine closely 1, 4
- Maintain adequate hydration 2
- Avoid concomitant nephrotoxic drugs 2
- Recent data shows ganciclovir increases risk of renal replacement therapy in pediatric transplant recipients (adjusted HR 1.84) 8
Administration Requirements
- IV infusion over 1 hour minimum 2
- In-line filter required 2
- Undiluted IV solution is highly alkaline (pH 11); avoid skin/mucous membrane contact 2
- Oral formulations must be taken with food to maximize bioavailability 4
Special Populations
Solid Organ Transplant Recipients
For prophylaxis in transplant recipients, standard dosing is 5 mg/kg/day IV or 1000 mg three times daily orally 4, 9. Duration varies by organ and immunosuppression level; liver transplant recipients received treatment through week 14 post-transplant in controlled trials 4.
High-risk patients (donor CMV+/recipient CMV-) have higher failure rates and may require more intensive regimens 9.
Valganciclovir Alternative
For adults: 900 mg orally twice daily for induction (21 days), then 900 mg once daily for maintenance 1. However, pediatric dosing data for valganciclovir are limited 1. When used in children, calculate dose as: 7 × body surface area × creatinine clearance (Schwartz method) 10.
Common Pitfalls to Avoid
- Failing to adjust for renal function: Even mild renal impairment (CrCl 50-70 mL/min) requires 50% dose reduction 11
- Underdosing in children: Oral ganciclovir requires 30 mg/kg every 8 hours in children, not adult dosing 1
- Inadequate monitoring: Check CBC/platelets frequently, especially in first weeks of therapy 4
- Ignoring drug interactions: Didanosine levels increase 111% when co-administered; monitor closely 4
- Improper IV administration: Must infuse over ≥1 hour; rapid infusion increases toxicity risk 2